Evidence map›Paper›PMID 37594632›Full record

ArticleHead and neck pathology2023

Loss of BAP1 Protein Expression by Immunohistochemistry in the Salivary Duct Carcinoma Component of an Intracapsular Carcinoma ex Pleomorphic Adenoma of the Parotid Gland.

Eleonora Fiorletta Quiroga, Patricia R Connor, Lisa Rooper, Mauricio A Moreno, J Stephen Nix

Open access · greenAbstract readCase Reports
In one paragraph

Article in Head and neck pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Eleonora Fiorletta QuirogaDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.ORCID http://orcid.org/0009-0009-1247-2228
Patricia R ConnorDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.ORCID http://orcid.org/0009-0008-5319-3404
Lisa RooperDepartment of Pathology, The Johns Hopkins Hospital, Baltimore, MD, 21287, USA.ORCID http://orcid.org/0000-0001-5636-9753
Mauricio A MorenoDepartment of Otolaryngology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.ORCID http://orcid.org/0000-0002-7015-625X
J Stephen NixDepartment of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA. jsnix@uams.edu.ORCID http://orcid.org/0000-0001-5386-3617
University of Arkansas for Medical Sciences · USJohns Hopkins Hospital · USUniversity of Arkansas Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBRCA1-associated protein 1 (BAP1) is a tumor suppressor gene that is altered in a variety of neoplasms as well as in BAP1 tumor predisposition syndrome. BAP1 alterations are associated with aggressive behavior in some malignancies and may have treatment implications in future. We present the first documented case of loss of BAP1 protein expression by immunohistochemistry in the salivary duct carcinoma (SDC) component of an intracapsular carcinoma ex pleomorphic adenoma (CXPA) in the context of molecular loss of function of BAP1 in the neoplasm.

methodsA woman of approximately 55 years of age presented with a deep parotid lobe mass, which was resected and found to be CXPA. BAP1 immunohistochemistry and next-generation sequencing was performed to further characterize the neoplasm.

resultsThe neoplasm showed loss of BAP1 protein expression in the SDC component but retention in the residual pleomorphic adenoma (PA). Next-generation sequencing confirmed a BAP1 loss of function alteration in the neoplasm.

conclusionThis is the first documented case report of BAP1 protein expression loss in the SDC component of a CXPA. Future studies are needed to investigate the relevance of BAP1 alterations in SDC and CXPA, which may have prognostic and treatment implications.

Indexed as

AdenocarcinomaAdenoma, PleomorphicCarcinoma, DuctalSalivary Gland NeoplasmsFemaleHumansImmunohistochemistryParotid GlandSalivary DuctsTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1 protein, humanTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1Carcinoma ex pleomorphic adenomaSalivary duct carcinomaSalivary gland neoplasm

Identifiers

PMID37594632
PMCPMC10514007
OpenAlexW4385968664

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.